Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S304000, C549S429000, C564S305000, C514S461000, C514S649000
Reexamination Certificate
active
07049329
ABSTRACT:
One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries.
REFERENCES:
patent: 2778826 (1957-01-01), Schmidle
patent: 5688825 (1997-11-01), Makriyannis et al.
patent: 5874459 (1999-02-01), Makriyannis et al.
patent: 5977180 (1999-11-01), Pate et al.
patent: 6200951 (2001-03-01), Gray et al.
patent: 6335023 (2002-01-01), Yu et al.
patent: 6399571 (2002-06-01), Gray et al.
patent: 6696412 (2004-02-01), Kelleher et al.
patent: 2002/0019444 (2002-02-01), Hogestatt et al.
patent: WO 01/92280 (2001-12-01), None
Pirdzhanov et al.,Arylalkylamine derivatives. IV. Synthesis of some substituted phenylrthylamines,,Armyanskii Khimicheskii Zhurnal (1972), 25(6),505-11.
Schmidle, CJ (1957): STN International, CAPLUS database, Columbus (Ohio), Accession No.: 1957:47302.
Database CAPLUS on STN, Acc. No. 1939:29763, Blicke, et al., ‘Antispasmodics. IV’ Journal of the American Chemical Society, (1939), 61, p. 774-6 (abstract, RN=6298-88-0).
International Search Report completed Aug. 23, 2003 and mailed Sep. 18, 2003.
Beltramo et al.; “Reversal of Dopamine D2Receptor Responses by Anandamide Transport Inhibitor”, The Journal of Neuroscience 20(9): 3401-3407, (May 1, 2000).
Beltramo et al.; “Functional Role of High-Affinity Anadaminde Transport, as Revealed by Selective Inhibition”, Science 277:1094-1097, (Aug. 22, 1997).
Giuffrida et al.; “Dopamine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum”, Nature Neuroscience 2(4): 358-363, (Apr. 1999).
Giuffrida et al.; “Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology”, The Journal of Pharmacology and Experimental Therapeutics, 298(1): Jul. 14, 2001.
Maccarrone et al.; “Anandamide Hydrolysis by Human Cells in Culture and Brain”, The Journal of Biological Chemistry, 273(48): 32332-32339, (Nov. 27, 1998).
Muthian et al.; “Synthesis and Characterization of a Fluorescent Substrate for the N-Arachidonoylethanolamine (Anandamide) Transmembrane Carrier1”, The Journal of Pharmacology and Experimental Therapeutics, 293(1):289-295 (2000).
Piomelli et al.; “Structural Determinants for Recognition and Translocation by the Anandamine Transporter”, Proc. Natl.Acad. Sci. USA, 96:5802-5807, (May 1999).
Piomelli et al.; “Endogenous Cannabinoid Signaling”, Neurobiology of Disease, 5: 462-473, (1998).
Rakhshan et al.; “Carrier-Mediated Uptake of the Endogenous Cannabinoid Anandamine in RBL-2H3 Cells 1”, The Journal of Pharmacology and Experimental Therapeutics, 292(3): 960-967, (2000).
Sheskin et al.; “Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor”, J. Med. Chem. 40: 659-667, (1997).
Aquila Brian M.
Hopkins Seth C.
Lockshin Curtis A.
Wang Fengjiang
Foley & Hoag LLP
Gordon Dana M.
Sepracor Inc.
Shameem Golam M. M.
LandOfFree
Amines that inhibit a mammalian anandamide transporter, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amines that inhibit a mammalian anandamide transporter, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amines that inhibit a mammalian anandamide transporter, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600599